Portfolio
1
companies
The latest investment brings total equity financing to £7.2m and will support clinical progression of internal assets.
"A third of all FDA-approved drugs target GPCRs, yet, despite decades of research and billions of funding, only a few GPCR-targeting antibodies exist. Thanks to the support of our investors, we are one step closer to making GPCRs and other challenging targets druggable, bringing needed therapies to patients across the globe."
.png)
The financing was supported by new investors including InnoSpark alongside returning backers such as the Development Bank of Wales.
"This is the most comprehensive validation of our platform thus far. While identifying antibodies to GPCRs has traditionally been a complex and time-intensive process requiring expensive specialist technology and training, we have demonstrated that Antiverse’s drug discovery platform can achieve this in a fraction of the time and cost. GPCRs are commercially interesting targets associated with various indications, and these antibodies offer a path to first in vivo results and can potentially be our first assets. I would like to thank our investors, this funding will enable us to continue to develop these assets in-house with our academic collaborators."
